Pharma & Biotech Archives - Page 3 of 109

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

CRC trials need faster evidence. KLEOS could test more therapies under one platform. Read why the model matters.

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.